THE EFFECT OF L-DOPA INFUSIONS WITH AND WITHOUT PHENYLALANINE CHALLENGES IN PARKINSONIAN-PATIENTS - PLASMA AND VENTRICULAR CSF L-DOPA LEVELS AND CLINICAL-RESPONSES

被引:21
|
作者
WOODWARD, WR
OLANOW, CW
BECKNER, RM
HAUSER, RA
GAUGER, LL
CEDARBAUM, JM
NUTT, JG
机构
[1] UNIV S FLORIDA,DEPT NEUROL,TAMPA,FL 33620
[2] UNIV S FLORIDA,DEPT PHARMACOL & EXPTL THERAPEUT,TAMPA,FL 33620
[3] CORNELL UNIV,MED CTR,DEPT NEUROL,NEW YORK,NY 10021
[4] OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201
[5] OREGON HLTH SCI UNIV,DEPT PHARMACOL,PORTLAND,OR 97201
关键词
D O I
10.1212/WNL.43.9.1704
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We monitored the motor response and plasma and ventricular CSF (CSF(v)) concentrations of L-dopa during IV infusions of L-dopa in two patients with advanced Parkinson's disease. Concentrations Of L-dopa in CSF(v) mirrored, but lagged behind, those in plasma. In the fasting state, the duration, but not the magnitude, of the motor response was greater with increasing plasma and CSF(v) levels Of L-dopa. During IV infusions of L-dopa following oral administration of phenylalanine, a large neutral amino acid that shares a transport system into the brain with L-dopa, the duration of the motor response was markedly attenuated despite undiminished CSF(v) levels of L-dopa. These observations suggest that either L-dopa entry into CSF(v) and the brain are differentially affected by phenylalanine or that phenylalanine affects other steps in the motor response. These observations demonstrate that, except in the fasting state, L-dopa in CSF(v) is not a reliable predictor of motor response.
引用
收藏
页码:1704 / 1708
页数:5
相关论文
共 50 条
  • [1] L-DOPA AND THE SECRETION OF SEBUM IN PARKINSONIAN-PATIENTS
    STREIFLER, M
    AVRAMI, E
    RABEY, JM
    [J]. EUROPEAN NEUROLOGY, 1980, 19 (01) : 43 - 48
  • [2] DOPAMINE L-DOPA RATIO IN CEREBROSPINAL-FLUID OF PARKINSONIAN-PATIENTS TREATED WITH L-DOPA + BENSERAZIDE
    FEKETE, M
    TARCZY, M
    BIHARI, K
    KATONA, G
    [J]. PSYCHOPHARMACOLOGY, 1984, 82 (1-2) : 93 - 94
  • [3] PLASMA LEVODOPA LEVEL AND CSF DOPAMINE L-DOPA RATIO IN SEVERELY DISABLED PARKINSONIAN-PATIENTS
    TAKATAS, A
    TARCZY, M
    HARSING, L
    BIHARI, K
    CSANDA, E
    [J]. NEW TRENDS IN CLINICAL NEUROPHARMACOLOGY: CALCIUM ANATONISTS, ACUTE NEUROLOGY, HEADACHE AND MOVEMENT DISORDERS, 1988, 7 : 286 - 288
  • [4] LACK OF LENGTHENING OF L-DOPA EFFECT BY DEPRENYL (SELEGILINE) IN PARKINSONIAN-PATIENTS
    RASCOL, O
    SENARD, JM
    SIMONETTA, M
    DEMONET, JF
    MONTASTRUC, JL
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1988, 2 (02) : 130 - 130
  • [5] CORRELATION OF CLINICAL SYMPTOMS, HVA AND 5-HIAA IN CSF AND PLASMA L-DOPA IN PARKINSONIAN PATIENTS TREATED WITH L-DOPA AND L-DOPA+RO4-4602
    CAMPANELLA, G
    ALGERI, S
    CERLETTI, C
    DOLFINI, E
    JORI, A
    RINALDI, F
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 11 (04) : 255 - 261
  • [6] PLASMA-CATECHOLAMINES AND THE ACUTE EFFECTS OF ORAL L-DOPA IN PARKINSONIAN-PATIENTS
    ROSSOR, M
    WATKINS, J
    BROWN, MJ
    REID, JL
    DOLLERY, CT
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1979, 9 (02) : 30 - 30
  • [7] PLASMA L-DOPA AND DOPAC LEVELS CORRELATE WITH CLINICAL-RESPONSE IN PARKINSONIAN-PATIENTS WITH THE ON-OFF PHENOMENON
    FREED, CR
    MURPHY, RC
    CLAY, KL
    CROWLEY, TJ
    JONES, RH
    HOEHN, MM
    [J]. CLINICAL RESEARCH, 1981, 29 (02): : A271 - A271
  • [8] ELECTRORETINOGRAMS AND VISUAL EVOKED CORTICAL POTENTIALS IN PARKINSONIAN-PATIENTS WITH OR WITHOUT L-DOPA TREATMENT
    GELMI, C
    SANDRINI, G
    MARTIGNONI, E
    BRUNO, A
    NAPPI, G
    TRIMARCHI, F
    [J]. NEURO-OPHTHALMOLOGY, 1992, 12 (02) : 125 - 132
  • [9] PERIPHERAL L-DOPA PHARMACOKINETICS IN UNTREATED, STABLE, AND FLUCTUATING PARKINSONIAN-PATIENTS
    GANCHER, ST
    NUTT, JG
    WOODWARD, W
    [J]. NEUROLOGY, 1986, 36 (04) : 216 - 216
  • [10] KALIURETIC EFFECT OF L-DOPA TREATMENT IN PARKINSONIAN PATIENTS
    GRANERUS, AK
    JAGENBURG, R
    SVANBORG, A
    [J]. ACTA MEDICA SCANDINAVICA, 1977, 201 (04): : 291 - 297